M
endelian randomization study designs represent new powerful tools available to researchers that enable causal inferences to be made about the effects of risk factors in health and disease outcomes in the context of a prospective observational study. [1] [2] [3] [4] These study designs involve estimating the association between a genetically modifiable risk factor and health and disease outcomes. 1, 2 If individuals with genetically lower or higher levels of a risk factor of interest are at greater or lesser risk of an outcome, then it can be inferred that the risk factor has a causal relationship to that outcome. [2] [3] [4] Provided that a chosen genetic variant is strongly associated with the risk factor of interest, is not associated with other factors that might affect the risk factor, and imparts its influence on a given outcome exclusively through its link to the risk factor, these causal inferences are considered to be robust. 2, 3 Mendelian randomization study designs have become increasingly popular among epidemiologists in recent years as recently completed genome-wide association and genome sequencing studies have substantially increased our knowledge of the genetic factors associated with health and disease. 1 Using Mendelian randomization techniques allows researchers to conduct studies that can make the kind of causal inferences that are typically only attainable from randomized controlled trials, thus avoiding much of expense, difficulty, and ethical issues that often arise with such trials. 1, 2, 4 Furthermore, as demonstrated in an exciting recent publication in Circulation Research, titled Exploring the Causal Pathway from Telomere Length to Coronary Heart Disease: A Network Mendelian Randomization Study by Zhan et al, 5 these study designs allow assessment of the influence of risk factors that are impossible to manipulate in humans, like telomere length, on disease outcomes and the complex network of factors that mediate this influence. 
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Although Mendelian randomization techniques can involve fairly computationally intensive analyses, the fundamental principles that guide these study designs are straightforward and if understood clearly should make articles that describe such techniques accessible to the average consumer of scientific literature. Thus, I would like to very briefly describe some of these principals before discussing the value of the article by Zhan at al 5 as an example of the ability of Mendelian randomization designs to address the complex biological relationships that exist between risk factors like telomere length and disease outcomes.
The basic premise behind these study designs lies in the fact that genetic variants recombine and randomly segregate during meiosis, such that their frequencies become randomly distributed within a population. 2, 3 This phenomenon creates a kind of natural randomized controlled trial, whereby risk alleles and normal control alleles are randomized within a population. Thus, when risk factor levels are linked to known genetic variants that can be measured and used to stratify study participants into risk allele and control allele groups, the confounding influence of all known and unknown factors on the association between the risk factor and a given outcome is minimized or excluded outright (a stepwise comparison with randomized controlled trials is depicted in the Figure) . 2, 3 What is more, Mendelian randomization effectively rules out the influence of reverse causality on the relationship between a risk factor and the observed outcome, as no outcome can selectively influence the segregation of alleles before conception. 2, 3 Thus, Mendelian randomization allows researchers to avoid many of the biases encountered in traditional observational studies that limit or prohibit inferences about causality and directionality. 3, 4 The idea to design these natural experiments was first proposed in a 1986 article by Katan 6 as a way to assess the causal link between low-density lipoprotein (LDL) and cancer risk. Observational studies at the time had established an association between lower LDL levels and higher cancer risk; however, it was impossible to conclude if LDL levels truly mediated cancer onset, if some unknown confounding factor both reduced LDL levels and increased cancer risk, or if cancer onset reduced LDL levels. 6 The proposed Mendelian randomization study was not conducted until 2009, when Trompet et al 7 concluded that individuals with a genetic variant of apolipoprotein E that caused chronic reductions in LDL levels had no increased risk for cancer compared with individuals harboring a normal control variant.
Recently, basic Mendelian randomization designs have been expanded to allow assessment of networks of factors that mediate the causal relationships between risk factors of interest and a given outcome. 1, 5 This modified Mendelian
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randomization model is often referred to as network Mendelian randomization. 5 Using a more basic Mendelian randomization study design, Scheller et al 8 recently demonstrated a causal role for genetically estimated telomere length in heart disease. However, the factors that mediate the link between telomere length and heart disease were unknown until publication of the aforementioned article by Zhan et al. 5 The authors used a network Mendelian randomization study design to evaluate for the first time the mediating role that a network of metabolic risk factors plays in the causal pathway between telomere length and coronary heart disease. 5 The examined metabolic risk factors were fasting insulin, fasting glucose, glycated hemoglobin, triglycerides, LDL, and total cholesterol levels, as well as diabetes mellitus diagnosis, body mass index, waist circumference, and hip:waist ratio. 5 The authors ultimately concluded that insulin lies within the causal pathway between genetically determined telomere length and heart disease, such that longer telomeres are linked with lower insulin levels, which in turn are linked to lower risk of heart disease. 5 One feature of this study that may be potentially confusing to readers was the use of a genomic marker as a genetically modulated risk factor. This element of the study is an important discussion point as it highlights one of the central assumptions of Mendelian randomization studies that must be met for results to be considered valid. This is the assumption that a chosen risk allele explains all or most of the variance in the risk factor of interest and acts on a given outcome exclusively through its effects on that risk factor. 2, 3 At first glance, telomere length may be interpreted by readers to be the risk allele and thus the genetic determinant of insulin levels. Likewise, it may seem that the authors have claimed that telomere length imparts its influence on coronary heart disease risk entirely through this link with insulin. As telomere dysfunction can lead to many downstream effects beyond insulin dysregulation, 9 which in turn could be mechanistically linked to heart disease, it would seem that the requirement for minimal pleiotropic effects of risk alleles has not been met by this study. However, telomere length was in fact the risk factor in this study, and a telomere length genetic risk score comprised of several telomere-related genes was used as the risk allele. 5 Indeed, these genes have minimal cellular effects beyond maintaining telomere length homeostasis, so they do not violate the requirement regarding pleiotropic effects of risk alleles. Furthermore, the authors conducted a comprehensive sensitivity analysis to rule out the influence of pleiotropy on their findings. 5 Mechanisms of endogenous genomic instability, such as telomere dysfunction, are generally considered to be difficult or impossible to manipulate in vivo in humans, which effectively rules out the possibility of designing randomized controlled trials to test the effects of such mechanisms on disease outcomes. Such hypothetical manipulations would also undoubtedly be considered unethical because of the inherent risk of adverse events resulting from systemically altering genomic features like telomeres in somatic tissues. Furthermore, genomic instability, like that caused by telomere dysfunction, can lead to a variety of cellular effects and fates depending on the tissues involved and environmental factors at play. 9 Thus, predicting which specific factors mediate the effects of a given mechanism of genomic instability on any particular disease outcome becomes problematic. As Zhan et al 5 have expertly demonstrated, expanded Mendel randomization study designs can be used to paint an unbiased picture of the complex network of factors that mediate the effects of telomere length on disease outcomes. The application of this study design by Zhan et al 5 in their recent article is thus an innovative and important approach to telomere-specific research questions. Likewise, the complex roles that other mechanisms of genomic instability play in disease outcomes may be well suited to examination by network Mendel randomization. Specifically, it would be very interesting to see such studies aimed at evaluating any causal relationships and mediating factors that exist between retroelement instability and cancer or heart disease risk, 10 centromeric instability and cancer risk, 11 or mitochondrial DNA deletions and muscle diseases. 12 Indeed, the future of Mendelian randomization studies may yield answers to many previously intractable biological questions.
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Figure. Mendelian randomization vs randomized controlled trials. Diagram illustrating a stepwise comparison of Mendelian randomization studies with randomized controlled trials. Key similarities in the 2 approaches are highlighted to illustrate how these fundamentally different study designs can be used to reach similar conclusions.
